First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants

被引：9
|
作者：
Huritz, Julia L. [1 ,2 ,4 ]
Lockey, Timothy D. [1 ,3 ]
Jones, Bart [1 ,2 ]
Freiden, Pamela [2 ]
Sealy, Robert [1 ,2 ]
Coleman, John [3 ]
Howlett, Nanna [2 ]
Branum, Kristen [2 ]
Slobod, Karen S. [2 ,5 ]
机构：
[1] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN USA
[3] St Jude Childrens Res Hosp, Dept Therapeut Prod & Quality, Memphis, TN USA
[4] Univ Tennessee, Dept Pathol, Knoxville, TN 37996 USA
[5] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Knoxville, TN 37996 USA
来源：
AIDS | 2008年 / 22卷 / 01期
关键词：
D O I：
10.1097/QAD.0b013e3282f174ed
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
To combat HIV-1 diversity, we are developing a multienvelope vaccine (comprising DNA, vaccinia virus and protein vectors). Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant.
引用
收藏
页码：149 / 151
页数：3
相关论文
共 50 条
  • [41] Two-year post-vaccination follow-up from APPROACH: Phase 1/2a randomized study evaluating safety and immunogenicity of prophylactic HIV vaccine regimens combining Ad26.Mos.HIV and gp140 envelope protein
    Tomaka, F.
    Stieh, D. J.
    Barouch, D. H.
    Robb, M. L.
    Michael, N. L.
    Lavreys, L.
    Nijs, S.
    Callewaert, K.
    Hendriks, J.
    Euler, Z.
    Pau, M. G.
    Schuitemaker, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 19 - 19
  • [42] Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection
    Leal, Lorna
    Guardo, Alberto C.
    Moron-Lopez, Sara
    Salgado, Maria
    Mothe, Beatriz
    Heirman, Carlo
    Pannus, Pieter
    Vanham, Guido
    van den Ham, Henk Jan
    Gruters, Rob
    Andeweg, Arno
    Van Meirvenne, Sonja
    Pich, Judit
    Arnaiz, Joan Albert
    Gatell, Josep M.
    Brander, Christian
    Thielemans, Kris
    Martinez-Picado, Javier
    Plana, Montserrat
    Garcia, Felipe
    AIDS, 2018, 32 (17) : 2533 - 2545
  • [43] Preliminary Study on the Role of Kynurenic Acid in Inhibiting the Physiological Changes of Astrocyte Induced By HIV-1 Envelope Protein gp120
    Chen, Xiaoliang
    Tang, Yi
    Wang, Zixuan
    Long, Min
    Cao, Hong
    BLOOD, 2023, 142
  • [44] Preclinical and Clinical Development of a Multi-Envelope, DNA-Virus-Protein (D-V-P) HIV-1 Vaccine
    Sealy, Robert
    Slobod, Karen S.
    Flynn, Patricia
    Branum, Kristen
    Surman, Sherri
    Jones, Bart
    Freiden, Pamela
    Lockey, Timothy
    Howlett, Nanna
    Hurwitz, Julia L.
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2009, 28 (1-2) : 49 - 68
  • [45] Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
    Bekker, Linda-Gail
    Moodie, Zoe
    Grunenberg, Nicole
    Laher, Fatima
    Tomaras, Georgia D.
    Cohen, Kristen W.
    Allen, Mary
    Malahleha, Mookho
    Mngadi, Kathryn
    Daniels, Brodie
    Innes, Craig
    Bentley, Carter
    Frahm, Nicole
    Morris, Daryl E.
    Morris, Lynn
    Mkhize, Nonhlanhla N.
    Montefiori, David C.
    Sarzotti-Kelsoe, Marcella
    Grant, Shannon
    Yu, Chenchen
    Mehra, Vijay L.
    Pensiero, Michael N.
    Phogat, Sanjay
    DiazGranados, Carlos A.
    Barnett, Susan W.
    Kanesa-thasan, Niranjan
    Koutsoukos, Marguerite
    Michael, Nelson L.
    Robb, Merlin L.
    Kublin, James G.
    Gilbert, Peter B.
    Corey, Lawrence
    Gray, Glenda E.
    McElrath, M. Juliana
    LANCET HIV, 2018, 5 (07): : E366 - E378
  • [46] Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial
    Hanke, T.
    Borthwick, N.
    Ahmed, T.
    Hayton, E. J.
    Ebrahimsa, U.
    Rose, A.
    Black, A.
    Yang, H.
    Hancock, G.
    Colloca, S.
    Nicosia, A.
    McMichael, A. J.
    Dorrell, L.
    IMMUNOLOGY, 2012, 137 : 517 - 518
  • [47] Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
    NJ Borthwick
    T Ahmed
    A Rose
    U Ebrahimsa
    A Black
    E Hayton
    H Yang
    G Hancock
    S Campion
    N Frahm
    S Colloca
    A Nicosia
    A McMichael
    L Dorrell
    T Hanke
    Retrovirology, 9
  • [48] Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
    Borthwick, N. J.
    Ahmed, T.
    Rose, A.
    Ebrahimsa, U.
    Black, A.
    Hayton, E.
    Yang, H.
    Hancock, G.
    Campion, S.
    Frahm, N.
    Colloca, S.
    Nicosia, A.
    McMichael, A.
    Dorrell, L.
    Hanke, T.
    RETROVIROLOGY, 2012, 9
  • [49] Evaluation of antiviral T cell responses and TSCM cells in volunteers enrolled in a phase I HIV-1 subtype C prophylactic vaccine trial in India
    Ponnan, Sivasankaran Munusamy
    Hayes, Peter
    Fernandez, Natalia
    Thiruvengadam, Kannan
    Pattabiram, Sathyamurthi
    Nesakumar, Manohar
    Srinivasen, Ashokkumar
    Kathirvel, Sujitha
    Shenker, Janani
    Goyal, Rajat
    Singla, Nikhil
    Mukherjee, Joyeeta
    Chatrath, Shweta
    Gilmour, Jill
    Subramanyam, Sudha
    Tripathy, Srikanth Prasad
    Swaminathan, Soumya
    Hanna, Luke Elizabeth
    PLOS ONE, 2020, 15 (02):
  • [50] Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies (vol 363, pg 79, 2007)
    Choudhry, Vidita
    Zhang, Mei-Yun
    Sidorov, Igor A.
    Louis, John M.
    Harris, Ilia
    Dimitrov, Antony S.
    Bouma, Peter
    Cham, Fatim
    Choudhary, Anil
    Rybak, Susanna M.
    Fouts, Timothy
    Montefiori, David C.
    Broder, Christopher C.
    Quinnan, Gerald V., Jr.
    Dimitrov, Dimiter S.
    VIROLOGY, 2007, 368 (02) : 431 - 431
12345